ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
11/12/2025
Voltar para busca
Dado oficial do USPTO
TETRAVARINEX
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
45
Atualização mais recente
13/12/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
30/05/2013
Data de registro
12/08/2014
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/02/2021
Última transação
13/12/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
709
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
98
Localização do titular
GB
Examinador
REEVES,APRIL ELIZABETH
Unidade examinadora
L20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Jazz Pharmaceuticals Research UK Limited
GW Research Limited
GW Pharma Limited
GW Pharma Limited
Representantes
Anessa Owen Kramer Honigman Miller Schwartz and Cohn LLP
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical and veterinary pharmaceutical preparationsherbsherbal extractsformulas containing herbal extractsmedicinal oils and pure extracts of medicinal plants and herbsfor use in the treatment of painmultiple sclerosisneuropathic painspinal cord injurybladder disfunctionperipheral neuropathycancer painperi-operative painrheumatoid arthritisinflammatory bowel diseaseneurogenic symptomspsychotic disordersdiseases of the central nervous systemstroke and head injurymotion sickness and chemically induced sicknessspasticityoncologycancer symptomspsychiatric illnessesneurodegenerative diseasesmetabolic disordersobesityobesity associated with type II diabetesbulimiaschizophreniaepilepsydravet syndromeneonatal hypoxiaseizuresalzheimersbone disordersdrugalcohol and nicotine abuseinflammatory disordersprotection of pancreatic islet cells in the treatment of diabetic or pre-diabetic patientsprotection of beta cells in the treatment of diabetic or pre-diabetic patientsmaintenance of insulin levelsimproved control of blood glucose levelstreatment of type I diabetestreatment of type II diabetes; pharmaceutical and veterinary pharmaceutical preparations for the treatment of painmultiple sclerosisneuropathic painspinal cord injurybladder disfunctionperipheral neuropathycancer painperi-operative painrheumatoid arthritisinflammatory bowel diseaseneurogenic symptomspsychotic disordersdiseases of the central nervous systemstroke and head injurymotion sickness and chemically induced sicknessspasticityoncologycancer symptomspsychiatric illnessesneurodegenerative diseasesmetabolic disordersobesityobesity associated with type II diabetesbulimiaschizophreniaepilepsydravet syndromeneonatal hypoxiaseizuresalzheimersbone disordersdrugalcohol and nicotine abuseinflammatory disordersprotection of pancreatic islet cells in the treatment of diabetic or pre-diabetic patientsprotection of beta cells in the treatment of diabetic or pre-diabetic patientsmaintenance of insulin levelsimproved control of blood glucose levelstreatment of type I diabetestreatment of type II diabetes; herbs for medicinal purposes; herb teas for medicinal purposes; plant extracts for pharmaceutical purposes
Publicações
Histórico de despachos e eventos da marca no USPTO.
45 publicações encontradas
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
30/01/2023
INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
28/12/2022
INPC
INVALIDATION PROCESSED
28/12/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
24/11/2021
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
26/10/2021
C71T
CANCELLED SECTION 71
26/02/2021
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
09/10/2019
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
12/08/2019
CHLD
CHANGE OF OWNER RECEIVED FROM IB
13/09/2018
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/12/2017
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
29/11/2017
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
29/11/2017
RNWL
INTERNATIONAL REGISTRATION RENEWED
15/12/2016
INNT
TOTAL INVALIDATION PROCESSED BY THE IB
24/09/2015
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
19/06/2015
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
30/01/2015
FICS
FINAL DISPOSITION NOTICE SENT TO IB
06/01/2015
FIMP
FINAL DISPOSITION PROCESSED
06/01/2015
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
12/11/2014
R.PR
REGISTERED-PRINCIPAL REGISTER
12/08/2014
GPNX
NOTIFICATION PROCESSED BY IB
13/06/2014
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
27/05/2014
PUBO
PUBLISHED FOR OPPOSITION
27/05/2014
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/05/2014
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/05/2014
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/05/2014
PBPR
WITHDRAWN FROM PUB - ESU SUPERVISOR REQUEST
22/04/2014
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
22/04/2014
ALIE
ASSIGNED TO LIE
18/04/2014
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
28/03/2014
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/03/2014
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/03/2014
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/03/2014
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
02/01/2014
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
02/01/2014
RFNT
REFUSAL PROCESSED BY IB
20/10/2013
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/09/2013
RFRR
REFUSAL PROCESSED BY MPU
25/09/2013
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
24/09/2013
CNRT
NON-FINAL ACTION WRITTEN
23/09/2013
DOCK
ASSIGNED TO EXAMINER
15/09/2013
MAFR
APPLICATION FILING RECEIPT MAILED
26/07/2013
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
22/07/2013
SDRC
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
18/07/2013
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TETRAVARINEX ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.